These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26237895)

  • 1. [New vaccines against group B meningococcal diseases].
    Hietalahti J; Meri S
    Duodecim; 2015; 131(6):525-32. PubMed ID: 26237895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
    Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.
    Veggi D; Bianchi F; Santini L; Lo Surdo P; Chesterman CC; Pansegrau W; Bechi N; Huang Y; Masignani V; Pizza M; Rappuoli R; Bottomley MJ; Cozzi R; Maione D
    PLoS Pathog; 2020 Oct; 16(10):e1008882. PubMed ID: 33007046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.
    Rossi R; Konar M; Beernink PT
    Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexsero: a multicomponent vaccine for prevention of meningococcal disease.
    Gorringe AR; Pajón R
    Hum Vaccin Immunother; 2012 Feb; 8(2):174-83. PubMed ID: 22426368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.
    Tzeng YL; Giuntini S; Berman Z; Sannigrahi S; Granoff DM; Stephens DS
    Infect Immun; 2020 Nov; 88(12):. PubMed ID: 32958529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.
    Johnson S; Tan L; van der Veen S; Caesar J; Goicoechea De Jorge E; Harding RJ; Bai X; Exley RM; Ward PN; Ruivo N; Trivedi K; Cumber E; Jones R; Newham L; Staunton D; Ufret-Vincenty R; Borrow R; Pickering MC; Lea SM; Tang CM
    PLoS Pathog; 2012; 8(10):e1002981. PubMed ID: 23133374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new vaccines against meningococcal disease.
    Bröker M
    Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
    Giuntini S; Pajon R; Ram S; Granoff DM
    Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential large scale production of meningococcal vaccines by stable overexpression of fHbp in the rice seeds.
    Ma J; Wang Y; Xu N; Jin L; Liu J; Xing S; Li X
    Protein Expr Purif; 2018 Dec; 152():1-6. PubMed ID: 29953946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines.
    Cayrou C; Akinduko AA; Mirkes EM; Lucidarme J; Clark SA; Green LR; Cooper HJ; Morrissey J; Borrow R; Bayliss CD
    PLoS One; 2018; 13(5):e0197186. PubMed ID: 29847547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.